ATE169304T1 - Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung - Google Patents

Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung

Info

Publication number
ATE169304T1
ATE169304T1 AT94911490T AT94911490T ATE169304T1 AT E169304 T1 ATE169304 T1 AT E169304T1 AT 94911490 T AT94911490 T AT 94911490T AT 94911490 T AT94911490 T AT 94911490T AT E169304 T1 ATE169304 T1 AT E169304T1
Authority
AT
Austria
Prior art keywords
permeability
functional domain
bactericide
biologically active
active peptides
Prior art date
Application number
AT94911490T
Other languages
English (en)
Inventor
Roger G Ii Little
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/030,644 external-priority patent/US5348942A/en
Application filed by Xoma Corp filed Critical Xoma Corp
Application granted granted Critical
Publication of ATE169304T1 publication Critical patent/ATE169304T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
AT94911490T 1993-03-12 1994-03-11 Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung ATE169304T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/030,644 US5348942A (en) 1993-03-12 1993-03-12 Therapeutic uses of bactericidal/permeability increasing protein products
US9320293A 1993-07-15 1993-07-15
US18322294A 1994-01-14 1994-01-14

Publications (1)

Publication Number Publication Date
ATE169304T1 true ATE169304T1 (de) 1998-08-15

Family

ID=27363684

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94911490T ATE169304T1 (de) 1993-03-12 1994-03-11 Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung

Country Status (11)

Country Link
EP (1) EP0690872B1 (de)
JP (3) JP4139863B2 (de)
AT (1) ATE169304T1 (de)
AU (1) AU694108B2 (de)
CA (1) CA2158058C (de)
DE (1) DE69412243T2 (de)
DK (1) DK0690872T3 (de)
ES (1) ES2123134T3 (de)
HK (1) HK1014191A1 (de)
NZ (1) NZ263344A (de)
WO (1) WO1994020532A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5858974A (en) * 1995-07-20 1999-01-12 Xoma Corporation Anti-fungal peptides
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
WO1995002414A1 (en) * 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
JPH08503490A (ja) 1993-08-18 1996-04-16 モルフォシス・ゲゼルシャフト・フュア・プロタインオプティミールング・ミット・ベシュレンクテル・ハフツング リポ多糖結合性および中和能のあるペプチド
AU695814B2 (en) * 1993-09-22 1998-08-20 Xoma Corporation Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic
EP0722333B1 (de) * 1993-10-05 2004-06-16 XOMA Technology Ltd. Bpi-protein-produkte für definierte funktionen des reticuloendothelialen systems
AU703211B2 (en) * 1994-01-14 1999-03-18 Xoma Corporation Anti-fungal methods and materials
EP0754050B1 (de) * 1994-01-14 2002-06-26 XOMA Technology Ltd. Anti gram positive bakterielle verfahren und mittel
US5447913A (en) 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5830860A (en) * 1994-03-24 1998-11-03 Regents Of The University Of Minnesota Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
JPH10508576A (ja) * 1994-09-15 1998-08-25 ゾーマ コーポレイション 抗真菌性ペプチド
US5851802A (en) * 1996-03-22 1998-12-22 Xoma Corporation Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
JP2000510845A (ja) * 1996-05-10 2000-08-22 ゾーマ コーポレイション ヒト髄膜炎菌血症のためのｂｐｉタンパク質産物の治療用途
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
CN1155403C (zh) * 1996-05-23 2004-06-30 爱克索马技术有限公司 杀细菌／通透性增加蛋白在制备用于治疗创伤出血病人的药物中的应用
US6486125B1 (en) 1996-05-24 2002-11-26 Regents Of The University Of Minnesota Synthesis of soluble β-sheet forming peptides
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
CA2298101A1 (en) * 1997-07-31 1999-02-11 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Novel synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome
US6013631A (en) 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6242219B1 (en) 1999-03-18 2001-06-05 Xoma (Us) Llc Methods for recombinant peptide production
US6515104B1 (en) 1999-06-25 2003-02-04 Xoma Technology Ltd. Therapeutic peptide-based constructs derived from domain II of bactericidal/permeability-increasing protein
US6423825B1 (en) 1999-06-25 2002-07-23 Xoma Technology Ltd. Therapeutic derivative compounds derived from domain II of bactericidal/permeability-increasing protein
DE60008749T2 (de) * 1999-06-25 2005-03-10 Xoma Technology Ltd., Berkeley Therapeutische peptide aus untersequenzen von bpi
WO2001003724A1 (en) * 1999-07-12 2001-01-18 Xoma Technology Ltd. Therapeutic uses of bpi protein products for inhibiting h+/k+ atpase activity
WO2003070751A2 (en) 2002-02-20 2003-08-28 Regents Of The University Of Minnesota Partial peptide mimetics and methods
EP2311962B1 (de) 2002-03-29 2013-03-13 XOMA Technology Ltd. Multigene Vectoren und Methoden für eine erhöhte Expression von rekombinanten Polypeptiden
SE0301431D0 (sv) * 2003-05-19 2003-05-19 Dermagen Novel antimicrobial peptides
US7878644B2 (en) 2005-11-16 2011-02-01 Gerber Scientific International, Inc. Light cure of cationic ink on acidic substrates
GB201319621D0 (en) * 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
GB201507722D0 (en) 2015-05-06 2015-06-17 Norwegian Univ Sci & Tech Ntnu Anti-bacterial agents and their use in therapy
GB201507723D0 (en) * 2015-05-06 2015-06-17 Norwegian Univ Sci & Tech Ntnu Anti-bacterial agents and their use in therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006279A1 (en) * 1985-04-30 1986-11-06 Scripps Clinic And Research Foundation Acute phase protein modulating endotoxic activity of lipopolysaccharides, compositions and methods
WO1992009621A1 (en) * 1990-12-03 1992-06-11 New York University Biologically active bactericidal/permeability-increasing protein fragments

Also Published As

Publication number Publication date
ES2123134T3 (es) 1999-01-01
NZ263344A (en) 1997-08-22
JP2005053921A (ja) 2005-03-03
CA2158058A1 (en) 1994-09-15
EP0690872B1 (de) 1998-08-05
JP4139863B2 (ja) 2008-08-27
DE69412243T2 (de) 1999-03-25
CA2158058C (en) 2000-08-01
JP2008101026A (ja) 2008-05-01
AU694108B2 (en) 1998-07-16
DK0690872T3 (da) 1999-05-10
DE69412243D1 (de) 1998-09-10
AU6398894A (en) 1994-09-26
EP0690872A1 (de) 1996-01-10
JPH08508248A (ja) 1996-09-03
HK1014191A1 (en) 1999-09-24
WO1994020532A1 (en) 1994-09-15

Similar Documents

Publication Publication Date Title
ATE169304T1 (de) Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
CA2181150A1 (en) Biologically Active Peptides from Functional Domains of Bactericidal/Permeability-Increasing Protein and Uses Thereof
BR0007597A (pt) Composição hipoalergênica contendo peptìdios tolerogênicos induzindo tolerância oral
PT749317E (pt) Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade
LU93259I2 (fr) LETIFEND (Protein Q)
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
BR9915982A (pt) Ensaio de seleção de peptìdeo aberta
ATE211391T1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
ATE152353T1 (de) Pharmazeutische zubereitungen auf der basis von bakteriozin und deren verwendung zur behandlung gastrointestinaler beschwerden
HUP0001458A2 (hu) Specifikus hasnyálmirigy lipáz inhibitor hatású peptidek, ezeket tartalmazó gyógyszerkészítmények és diagnosztikai reagensek, valamint ezek alkalmazása
DE69840024D1 (de) Antimikrobielle Peptide, abstammend von Ubiquicidin
DE60138703D1 (de) Transportpeptide abgeleitet von erns protein
ATE373091T1 (de) Verfahren zur gewinnung und anwendung neuer humaner defensine als biologisch aktive eiweisstoffe zur behandlung von infektionen und anderen erkrankungen
DE69535460D1 (de) Pharmazeutische peptide formulierungen zur behandlung von staubmilben allergie
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
DE69738600D1 (de) Neuroaktive peptide
ATE346091T1 (de) Neues diagnostisches reagens und kit zur erkennung von rickettsiose
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DE60234843D1 (de) Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
DK0811068T3 (da) Humane DNase I varianter
DE59611330D1 (de) Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen
ATE260934T1 (de) Therapeutische peptide aus untersequenzen von bpi
WO1998056810A3 (de) Humanes protein lus-i, seine herstellung und verwendung
Critical Care Society of South Africa Working Group Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee